The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 345:291-292 July 26, 2001 Number 4
NextNext

A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Turpie et al. (March 1 issue)1 report the findings of a rigorously performed double-blind, randomized trial comparing a synthetic pentasaccharide (Org31540/SR90107A) and a low-molecular-weight heparin (enoxaparin) in patients undergoing total hip replacement. The patients were randomly assigned to receive one of five daily doses of the pentasaccharide beginning 6 hours postoperatively (range, 4 to 8) or enoxaparin beginning 12 to 24 hours postoperatively. Two studies2,3 evaluated the effect of prophylaxis with low-molecular-weight heparin administered in close proximity to surgery, either within two hours before surgery or six hours after surgery, in patients undergoing elective hip surgery and . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.